For projects requiring hundreds of millions, fundraising should be split into phases. The initial "pre-industrialization" phase, focused on proving technology, is suited for venture capital. Later phases for manufacturing and scaling should target project finance structures with debt/equity combinations and strategic partners.

For early-stage MedTech startups, key milestones for investors are not just regulatory successes. They are fundamental proofs of concept—showing the device works in a model and demonstrating how it would function in a clinical setting. This builds an investor's vision of the product's future.

The reality of hospital value analysis committees means product adoption takes years. Entrepreneurs must build this lengthy timeline into financial models and fundraising to ensure survival, rather than projecting rapid uptake.

Midjourney's financial independence from venture capital gives its founder, David Holz, the freedom to pursue ambitious, capital-intensive hardware projects. This kind of bold, non-adjacent expansion is rarely possible for VC-backed startups who are locked into a cycle of hitting specific KPIs to secure their next funding round.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

The robotic platform's success was driven by a physician-founder's focus on three core needs: being precise and efficient, being user-friendly by working with all existing third-party devices, and being affordable for hospitals.

Shkreli argues that revolutionary hardware ventures require exceptionally long time horizons, making traditional VCs unsuitable partners due to their fund cycles. He suggests targeting corporate investors who understand and can stomach a 15-20 year development runway.

Arcus navigated its capital-intensive early years by using strategic collaborations to bring in over $1 billion in largely non-dilutive funding. This approach allowed the company to reach late-stage clinical milestones and generate valuable data, bridging the gap to a point where public market investors could see tangible value.